Regulation, Innovation and Competition in Pharmaceutical Markets: A Comparative Study

Antitrust / Competition Law › Intellectual Property / Patent / Copyright › Medical Law

Regulation, Innovation and Competition in Pharmaceutical Markets: A Comparative Study

By Margherita Colangelo
Hart Publishing October 2024

Specifications

ISBN-13
9781509965557
Publisher
Hart Publishing
Publication
October 2024
Format
Paperback
Jurisdiction
U.K. ? Countri(es) for reference only

Also available as

Hardback

Details

This book explores the fundamental and inextricable relationship between regulation, intellectual property, competition laws, and public health in prescription drugs markets, examining their interconnections and the delicate balance between the various interests and policy goals at stake.

Although pharmaceutical markets are heavily regulated and subject to close antitrust scrutiny, there is a constant requirement for existing rules and policies to tackle a number of persistent, complex issues. The variety of anticompetitive practices occurring in this sector, the worrying rise in drug prices, and major, far-reaching concerns over the accessibility of medicines are sources of frequent controversy in academic and policy debate. Understanding the unique features and dynamics of the pharmaceutical industry requires a tailored and multifaceted approach.

The study is enhanced by the adoption of a comparative perspective, tracing convergence and divergence between EU and US systems through the analysis of relevant applicable rules, emblematic case studies, and policy choices. Pursuant to this rigorous approach, the book provides an original and thought-provoking critique of the challenges of regulating pharmaceutical markets.

Table of Contents

Acknowledgements v

Introduction 1
I. The Different Faces of Pharmaceutical Markets 1
II. Purpose and Scope of the Analysis 3
III. Methodology 7
IV. Structure of the Book 9

PART I
1. Regulating Entry 15
I. The Main Features of Pharmaceutical Markets: The Supply Side and the Demand Side 15
II. The Product Life Cycle and the Costs of Innovation 20
III. The Access to the Market: Regulatory Approaches 23
A. The European Regulatory Framework 23
B. The US Regulatory Framework 27
IV. Concluding Remarks 33
2. Regulating Exclusivity 34
I. The Interplay between Regulatory Exclusivities and Intellectual Property Rights 34
II. Intellectual Property Rights in the Pharmaceutical Industry: An Overview on the Role of Patents 35
III. EU Supplementary Protection Certificate and US Patent Term Restoration 41
IV. Regulatory Exclusivity 48
V. Research and Bolar Exemptions 52
VI. Exhaustion Doctrine and Parallel Trade 59
VII. Concluding Remarks 63
3. Regulating Prices 64
I. Pharmaceutical Pricing and Reimbursement Systems in Europe 64
II. The US System 70
III. Concluding Remarks 76
viii Contents

PART II
4. Competition Law Enforcement in Pharmaceutical Markets: An Introduction 79
I. EU and US Antitrust Rules: An Essential Overview 79
II. Antitrust Enforcement in the Pharmaceutical Sector 87
III. Market Definition 95
IV. Concluding Remarks 100
5. Reverse Payment Patent Settlements 102
I. The Recurrence of Reverse Payment Patent Settlements in Pharmaceutical Markets 102
II. Reverse Payment Patent Settlements in the United States 105
A. Earlier Case Law and the Actavis Ruling 105
B. Critical Issues after Actavis 109
C. Further Developments 113
III. EU Case Law on Reverse Payment Patent Settlements 119
A. Lundbeck 120
B. Generics 123
IV. Comparative Analysis 127
A. Legal Frameworks 127
B. The Antitrust Assessment 129
V. Concluding Remarks 134
6. Product Hopping 136
I. Pharmaceutical Product Reformulations 136
II. Product Hopping before US Courts 140
III. The EU Experience 146
IV. The Antitrust Assessment of Product Reformulation 151
V. Concluding Remarks 155
7. Excessive Drug Pricing 157
I. The Resurgence of Excessive Pricing Cases in the Pharmaceutical Sector 157
II. Excessive Pricing under EU Competition Law 161
A. Aspen 165
III. The US Approach 169
IV. The Role of Antitrust Enforcement on Excessive Drug Prices 176
V. Concluding Remarks 178
Contents ix

PART III
8. Further Interactions: Pharmaceutical Markets, Intellectual Property and Human Rights 183
I. The Right to Health and Access to Medicines and the Relationship with Intellectual Property Rights: An Overview 183
II. Compulsory Licensing 191
III. Concluding Remarks 196
9. Public Health and Public Interest in Competition Law 198
I. Public Health and Competition Law 198
II. Competition Law and Non-competition Interests 203
III. Concluding Remarks 208
Conclusion 209
Bibliography 213
Index 233
HKD 542.10 −3%
HKD 558.87

Inclusive of HK delivery

Ready to ship
Delivery Time: around 4-5 weeks
Extra 10 working days if shipping address outside Hong Kong
  • Free HK shipping over HK$1,000
  • International shipping to 35+ countries
Order Form
Save

Recommended

You may also be interested in these books:

More titles from Antitrust / Competition Law

View all
United States v. Apple : Competition in America
Harvard University Press

United States v. Apple : Competition in America

Chris Sagars
HKD 331.84
Natural Monopolies in Digital Platform Markets
Cambridge University Press

Natural Monopolies in Digital Platform Markets

Francesco Ducci
HKD 1,374.49
EU Competition and State Aid Rules: Public and Private Enforcement
Springer-Verlag

EU Competition and State Aid Rules: Public and Private Enforcement

Vesna Tomljenović; Nada Bodiroga-Vukobrat; Vlatka Butorac Malnar; Ivana Kunda
HKD 1,994.00
Rethinking Exclusionary Abuses in EU Competition Law
Hart Publishing

Rethinking Exclusionary Abuses in EU Competition Law

Ekaterina Rousseva
HKD 2,269.80
FRAND: German Case Law and Global Perspectives
Edward Elgar Publishing

FRAND: German Case Law and Global Perspectives

Peter Georg Picht; Thomas F. Cotter; Erik Habich
HKD 2,698.54
Sport and EU Competition Law: An Introductory Guide Pre-order
Edward Elgar Publishing

Sport and EU Competition Law: An Introductory Guide

Estelle Ivanova; Ian Blackshaw
HKD 844.87